Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Pedro M Folegatti"'
Autor:
Sue Ann Costa Clemens, Pedro M. Folegatti, Katherine R. W. Emary, Lily Yin Weckx, Jeremy Ratcliff, Sagida Bibi, Ana Verena De Almeida Mendes, Eveline Pipolo Milan, Ana Pittella, Alexandre V. Schwarzbold, Eduardo Sprinz, Parvinder K. Aley, David Bonsall, Christophe Fraser, Michelle Fuskova, Sarah C. Gilbert, Daniel Jenkin, Sarah Kelly, Simon Kerridge, Teresa Lambe, Natalie G. Marchevsky, Yama F. Mujadidi, Emma Plested, Maheshi N. Ramasamy, Peter Simmonds, Tanya Golubchik, Merryn Voysey, Andrew J. Pollard, the AMPHEUS Project, Oxford COVID Vaccine Trial Team
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-10 (2021)
Emerging variants of SARS-CoV-2 raise concerns about vaccine efficiency. Here, the authors present a post-hoc analysis for the ChAdOx1 nCoV-19 (AZD1222) vaccine trial in Brazil and provide efficacy against symptomatic COVID-19 caused by the Zeta (P.2
Externí odkaz:
https://doaj.org/article/2174b542d59f4531bfbfd908fa719572
Autor:
Pedro M. Folegatti, Kate Harrison, Lorena Preciado-Llanes, Fernando Ramos Lopez, Mustapha Bittaye, Young Chan Kim, Amy Flaxman, Duncan Bellamy, Rebecca Makinson, Jonathan Sheridan, Sasha R. Azar, Rafael Kroon Campos, Mark Tilley, Nguyen Tran, Daniel Jenkin, Ian Poulton, Alison Lawrie, Rachel Roberts, Eleanor Berrie, Shannan L. Rossi, Adrian Hill, Katie J. Ewer, Arturo Reyes-Sandoval
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-10 (2021)
Chikungunya virus (CHIKV) is a reemerging mosquito-borne virus that has caused outbreaks in various regions of the world. Here the authors present safety and immunogenicity data from a phase 1 trial with the simian adenovirus vectored vaccine ChAdOx1
Externí odkaz:
https://doaj.org/article/e71818edfedb43ec92d1c8c53528e12d
Autor:
Jo Salkeld, Yrene Themistocleous, Jordan R. Barrett, Celia H. Mitton, Thomas A. Rawlinson, Ruth O. Payne, Mimi M. Hou, Baktash Khozoee, Nick J. Edwards, Carolyn M. Nielsen, Diana Muñoz Sandoval, Florian A. Bach, Wiebke Nahrendorf, Raquel Lopez Ramon, Megan Baker, Fernando Ramos-Lopez, Pedro M. Folegatti, Doris Quinkert, Katherine J. Ellis, Ian D. Poulton, Alison M. Lawrie, Jee-Sun Cho, Fay L. Nugent, Philip J. Spence, Sarah E. Silk, Simon J. Draper, Angela M. Minassian
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
In endemic settings it is known that natural malaria immunity is gradually acquired following repeated exposures. Here we sought to assess whether similar acquisition of blood-stage malaria immunity would occur following repeated parasite exposure by
Externí odkaz:
https://doaj.org/article/e073d6a50a334532bed97edf79803bd5
Autor:
Ane Ogbe, Matthew Pace, Mustapha Bittaye, Timothy Tipoe, Sandra Adele, Jasmini Alagaratnam, Parvinder K. Aley, M. Azim Ansari, Anna Bara, Samantha Broadhead, Anthony Brown, Helen Brown, Federica Cappuccini, Paola Cinardo, Wanwisa Dejnirattisai, Katie J. Ewer, Henry Fok, Pedro M. Folegatti, Jamie Fowler, Leila Godfrey, Anna L. Goodman, Bethany Jackson, Daniel Jenkin, Mathew Jones, Stephanie Longet, Rebecca A. Makinson, Natalie G. Marchevsky, Moncy Mathew, Andrea Mazzella, Yama F. Mujadidi, Lucia Parolini, Claire Petersen, Emma Plested, Katrina M. Pollock, Thurkka Rajeswaran, Maheshi N. Ramasamy, Sarah Rhead, Hannah Robinson, Nicola Robinson, Helen Sanders, Sonia Serrano, Tom Tipton, Anele Waters, Panagiota Zacharopoulou, Eleanor Barnes, Susanna Dunachie, Philip Goulder, Paul Klenerman, Gavin R. Screaton, Alan Winston, Adrian V.S. Hill, Sarah C. Gilbert, Miles Carroll, Andrew J. Pollard, Sarah Fidler, Julie Fox, Teresa Lambe, John Frater
Publikováno v:
JCI Insight, Vol 7, Iss 7 (2022)
Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable vir
Externí odkaz:
https://doaj.org/article/446dfee8ec4944f5951afc9fd4bc0066
Autor:
Pedro M Folegatti, Daniel Jenkin, Susan Morris, Sarah Gilbert, Denny Kim, James S. Robertson, Emily R. Smith, Emalee Martin, Marc Gurwith, Robert T. Chen
Publikováno v:
Vaccine. 40:5248-5262
Replication-deficient adenoviral vectors have been under investigation as a platform technology for vaccine development for several years and have recently been successfully deployed as an effective COVID-19 counter measure. A replication-deficient a
Autor:
Chris Butler, Chris Ellis, Pedro M. Folegatti, Hannah Swayze, Julie Allen, Louise Bussey, Duncan Bellamy, Alison Lawrie, Elizabeth Eagling-Vose, Ly-Mee Yu, Milensu Shanyinde, Catherine Mair, Amy Flaxman, Katie Ewer, Sarah Gilbert, Thomas G. Evans, on behalf of the INVICTUS Investigators
Publikováno v:
Vaccines, Vol 9, Iss 8, p 851 (2021)
Background: Pre-existing T cell responses to influenza have been correlated with improved clinical outcomes in natural history and human challenge studies. We aimed to determine the efficacy, safety and immunogenicity of a T-cell directed vaccine in
Externí odkaz:
https://doaj.org/article/07e4a3fa2ad845ab89602386d2116940
Autor:
Daniel Jenkin, Daniel Wright, Pedro M Folegatti, Abigail Platt, Ian Poulton, Alison Lawrie, Nguyen Tran, Amy Boyd, Cheryl Turner, John N Gitonga, Henry K Karanja, Daisy Mugo, Katie J Ewer, Thomas A Bowden, Sarah C Gilbert, Bryan Charleston, Pontiano Kaleebu, Adrian V S Hill, George M Warimwe
Publikováno v:
The Lancet Infectious Diseases.
Autor:
Pedro M. Folegatti, Amy Flaxman, Daniel Jenkin, Rebecca Makinson, Lucy Kingham-Page, Duncan Bellamy, Fernando Ramos Lopez, Jonathan Sheridan, Ian Poulton, Jeremy Aboagye, Nguyen Tran, Celia Mitton, Rachel Roberts, Alison M. Lawrie, Adrian V. S. Hill, Katie J. Ewer, Sarah Gilbert
Publikováno v:
Vaccines, Vol 9, Iss 3, p 262 (2021)
Heterologous prime-boost strategies are known to substantially increase immune responses in viral vectored vaccines. Here we report on safety and immunogenicity of the poxvirus Modified Vaccinia Ankara (MVA) vectored vaccine expressing four Mycobacte
Externí odkaz:
https://doaj.org/article/3e8281ba4494441aaae4e83953650bf7
Autor:
Merryn Voysey, Amy Flaxman, Jeremy Aboagye, Parvinder K Aley, Sandra Belij-Rammerstorfer, Sagida Bibi, Mustapha Bittaye, Federica Cappuccini, Sue Charlton, Elizabeth A Clutterbuck, Sophie Davies, Christina Dold, Nick J Edwards, Katie J Ewer, Saul N Faust, Pedro M Folegatti, Jamie Fowler, Ciaran Gilbride, Sarah C Gilbert, Leila Godfrey, Bassam Hallis, Holly E Humphries, Daniel Jenkin, Simon Kerridge, Yama F Mujadidi, Emma Plested, Maheshi N Ramasamy, Hannah Robinson, Helen Sanders, Matthew D Snape, Rinn Song, Kelly M Thomas, Marta Ulaszewska, Danielle Woods, Daniel Wright, Andrew J Pollard, Teresa Lambe
The trajectory of immune responses following the primary dose series determines the decline in vaccine effectiveness over time. Here we report on maintenance of immune responses during the year following a two-dose schedule of ChAdOx1 nCoV-19/AZD1222
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ca008dfeea2ae68ee3c352ef24ca2bb
https://doi.org/10.1093/cei/uxad013
https://doi.org/10.1093/cei/uxad013
Autor:
Pedro M. Folegatti, Duncan Bellamy, Rachel Roberts, Jonathan Powlson, Nick J. Edwards, Catherine F. Mair, Georgina Bowyer, Ian Poulton, Celia H. Mitton, Nicky Green, Eleanor Berrie, Alison M. Lawrie, Adrian V.S. Hill, Katie J. Ewer, John Hermon-Taylor, Sarah C. Gilbert
Publikováno v:
Vaccines, Vol 7, Iss 2, p 40 (2019)
Adenovirus vectored vaccines are a highly effective strategy to induce cellular immune responses which are particularly effective against intracellular pathogens. Recombinant simian adenovirus vectors were developed to circumvent the limitations impo
Externí odkaz:
https://doaj.org/article/972193b6a1c54ddca8bc7ac33f7fdf5c